Exploration of Neuroscience

Table 3. Absorption.

S/N	PubChem ID	Caco-2	P-gp inhibitor	P-gp substrate	HIA	F20
1	26970	–4.91692	0.506035	0.453835	0.130786	0.337263
2	538757	–4.58667	0.031898	0.283576	0.103385	0.31135
3	119838	–4.63054	0.047404	0.699422	0.061999	0.242071
4	569521	–4.63073	0.326623	0.002526	0.000258	0.027004
5	137829	–4.78276	0.437001	0.044625	0.0359	0.040214
6	536968	–4.62449	0.531487	0.019897	0.003222	0.128571
7	573554	–4.65035	0.04902	0.00817	0.002036	0.08497
8	8973	–5.06839	0.000599	0.527373	0.641476	0.638851
9	29775	–4.85237	0.061809	0.315019	0.147846	0.11865
10	31260	–4.9408	0.049431	0.185502	0.057565	0.077856
11	68165	–4.68714	0.356785	0.446496	0.088581	0.095654
12	7884	–4.72624	0.072895	0.321348	0.004368	0.008132
13	538762	–4.97157	0.446541	0.010968	0.123754	0.369889
14	14818495	–4.63716	0.448093	0.508415	0.000399	0.11527
15	102967	–4.67784	0.549146	0.115956	0.011051	0.036225
16	18632	–4.51273	0.519347	0.310718	0.077114	0.127536
17	536113	–4.49542	0.185111	0.098039	0.023363	0.147535
18	243	–3.9969	0.002589	0.191664	0.057402	0.018149
19	569842	–4.93789	0.004658	3.11E-05	1.17E-05	0.000296
20	10866899	–4.50862	0.351914	0.239918	0.002181	0.135434
21	519408	–4.49845	0.48402	0.530153	0.070005	0.199272
22	5364923	–4.53857	0.341789	0.273713	0.071465	0.123894
23	555485	–4.73694	0.033727	0.442947	0.216055	0.102074
24	69275	–4.72676	0.279591	0.037793	0.031292	0.0655
25	8390	–4.40037	0.017006	0.029411	0.000926	0.008216
26	542173	–4.97635	0.012524	0.015364	0.023056	0.163634
27	542172	–4.94061	0.147919	0.024932	0.089424	0.112078
28	547752	–4.57741	0.310443	0.297325	0.072284	0.121186
29	547974	–4.59355	0.557676	0.539588	0.12346	0.217929
30	10975	–4.86772	0.13327	0.056342	0.00692	0.066806
31	361986	–4.97256	0.027072	0.401648	0.33755	0.27611
32	564977	–4.43907	0.148721	0.038275	0.004756	0.008511
33	533436	–4.83576	0.17724	0.080831	0.195407	0.044866
34	12174	–4.54272	0.482673	0.140507	0.285048	0.615153
35	637517	–5.08013	0.001252	0.001289	0.109114	0.547337
36	5364506	–5.01246	0.40957	0.009203	0.024098	0.641314

Return to article view

Supplementary materials

The supplementary tables for this article are available at: https://www.explorationpub.com/uploads/Article/file/1006152_sup_1.pdf. Other supplementary material for this article is available at: https://www.explorationpub.com/uploads/Article/file/1006152_sup_2.pdf.

Declarations

Author contributions

MNM: Conceptualization, Methodology, Writing—original draft, Writing—review & editing, Formal analysis. NIA: Investigation, Writing—original draft, Writing—review & editing. OMA: Investigation, Writing—original draft, Writing—review & editing. OHA: Investigation, Writing—original draft, Writing—review & editing. ATO: Investigation, Writing—original draft, Writing—review & editing. YAA: Investigation, Writing—original draft, Writing—review & editing. AOR: Writing—review & editing. MFO: Investigation, Writing—original draft, Writing—review & editing. OOA: Conceptualization, Writing—review & editing, Supervision, Project administration. All authors read and approved the submitted version.

Conflicts of interest

The authors declare that they have no conflicts of interest.

Ethical approval

Not applicable.

Consent to participate

Not applicable.

Consent to publication

Not applicable.

Availability of data and materials

The datasets (the associated disease genes and the compound targets) used for this study can be found in GeneCard, SwissTargetPrediction, and Superpred.

Funding

This research received no external funding.

Copyright

Publisher’s note

Open Exploration maintains a neutral stance on jurisdictional claims in published institutional affiliations and maps. All opinions expressed in this article are the personal views of the author(s) and do not represent the stance of the editorial team or the publisher.

References

Dickson DW. Launch of american journal of neurodegenerative disease. Am j neurodegener dis. 2012;1:i–ii. [PubMed] [PMC]

Nakajima A, Ohizumi Y. Potential Benefits of Nobiletin, A Citrus Flavonoid, against Alzheimer’s Disease and Parkinson’s Disease. Int J Mol Sci. 2019;20:3380. [DOI] [PubMed] [PMC]

Lane CA, Hardy J, Schott JM. Alzheimer’s disease. Eur J Neurol. 2018;25:59–70. [DOI] [PubMed]

Kalia LV, Lang AE. Parkinson’s disease. Lancet. 2015;386:896–912. [DOI] [PubMed]

DeTure MA, Dickson DW. The neuropathological diagnosis of Alzheimer’s disease. Mol Neurodegener. 2019;14:32. [DOI] [PubMed] [PMC]

Picca A, Calvani R, Coelho-Junior HJ, Landi F, Bernabei R, Marzetti E. Mitochondrial Dysfunction, Oxidative Stress, and Neuroinflammation: Intertwined Roads to Neurodegeneration. Antioxidants. 2020;9:647. [DOI] [PubMed] [PMC]

Röhl C, Armbrust E, Herbst E, Jess A, Gülden M, Maser E, et al. Mechanisms Involved in the Modulation of Astroglial Resistance to Oxidative Stress Induced by Activated Microglia: Antioxidative Systems, Peroxide Elimination, Radical Generation, Lipid Peroxidation. Neurotox Res. 2010;17:317–31. [DOI] [PubMed]

Singh S, Swarnkar S, Goswami P, Nath C. Astrocytes and Microglia: Responses to Neuropathological Conditions. Int J Neurosci. 2011;121:589–97. [DOI] [PubMed]

Higgins GC, Beart PM, Shin YS, Chen MJ, Cheung NS, Nagley P. Oxidative Stress: Emerging Mitochondrial and Cellular Themes and Variations in Neuronal Injury. J Alzheimer’s Dis. 2010;20:S453–73. [DOI] [PubMed]

10.

Luthra R, Roy A. Role of Medicinal Plants against Neurodegenerative Diseases. Curr Pharm Biotechnol. 2022;23:123–39. [DOI] [PubMed]

11.

Venkatesan R, Ji E, Kim SY. Phytochemicals That Regulate Neurodegenerative Disease by Targeting Neurotrophins: A Comprehensive Review. BioMed Res Int. 2015;2015:814068. [DOI] [PubMed] [PMC]

12.

Gade J, Sivaraj K. Evaluation of Phyllanthus amarus herb for its hepatic effects. J Drug Deliv Ther. 2019;9:249–51. [DOI]

13.

M PE. Herbal drug treatment for liver disorders: therapeutic potential of Phyllanthus amarus. Int J Indig Herbs Drugs. 2026;11:7–13. [DOI]

14.

Onyeukwu OB, Njideaka OT, Dibie DC. The antioxidant and phytochemical analysis of methanol extract of Phyllanthus amarus. FUDMA J OF SCI. 2024;8:295–9. [DOI]

15.

Gbayisomore TJ, Alex GS, Iteire KA, Adedotun OA. Medicinal plants commonly used in Africa with neuroprotective potential in Alzheimer’s disease: Mechanisms and translational relevance. Adv Neurol. 2025;0:025190050. [DOI]

16.

Gautam G. Network Pharmacology-Based Validation of Traditional Therapeutic Claim of Momordica Charantiain Alleviating Diabetic Nephropathy. J CAM Res Prog. 2022;1:e1. [DOI]

17.

Tay ELE, Leong H, Cheng K. Network Pharmacology and Molecular Docking Elucidate Key Targets and Multi-Pathway Modulation in the Antidiabetic Action of Momordica charantia L. J Bioprocess Biomass Technol. 2025;4:43–9. [DOI]

18.

Rivera RG Jr, Regidor PJS, Ruamero EC, Delos Santos CDR, Gomez CB, Allanigue EJV, et al. Applying Network Pharmacology and Molecular Docking in the Screening for Molecular Mechanisms of Ampalaya (Momordica charantia L.) and Banaba (Lagerstroemia speciosa L.) against Type 2 Diabetes Mellitus. Acta Med Philipp. 2023;58:108–24. [DOI] [PubMed] [PMC]

19.

Argueti-Ostrovsky S, Alfahel L, Kahn J, Israelson A. All Roads Lead to Rome: Different Molecular Players Converge to Common Toxic Pathways in Neurodegeneration. Cells. 2021;10:2438. [DOI] [PubMed] [PMC]

20.

Ganguly G, Chakrabarti S, Chatterjee U, Saso L. Proteinopathy, oxidative stress and mitochondrial dysfunction: cross talk in Alzheimer's disease and Parkinson's disease. Drug Des Dev Ther. 2017;11:797–810. [DOI] [PubMed] [PMC]

21.

Ismail EN, Jantan I, Vidyadaran S, Jamal JA, Azmi N. Phyllanthus amarus prevents LPS-mediated BV2 microglial activation via MyD88 and NF-κB signaling pathways. BMC Complement Med Ther. 2020;20:202. [DOI] [PubMed] [PMC]

22.

Dong X. Current Strategies for Brain Drug Delivery. Theranostics. 2018;8:1481–93. [DOI] [PubMed] [PMC]

23.

Liu X, Chen C, Smith BJ. Progress in Brain Penetration Evaluation in Drug Discovery and Development. J Pharmacol Exp Ther. 2008;325:349–56. [DOI] [PubMed]

24.

Blossom V, Ullal SD, D’Souza MM, Ranade AV, Kumar NA, Rai R. Implicating neuroinflammation in hippocampus, prefrontal cortex and amygdala with cognitive deficit: a narrative review. 3 Biotech. 2025;15:320. [DOI] [PubMed] [PMC]

25.

Soofi A, Taghizadeh M, Tabatabaei SM, Rezaei Tavirani M, Shakib H, Namaki S, et al. Centrality Analysis of Protein-Protein Interaction Networks and Molecular Docking Prioritize Potential Drug-Targets in Type 1 Diabetes. Iran J Pharm Res. 2020;19:121–34. [DOI] [PubMed] [PMC]

26.

Dharshini LCP, Sakthivel KM, Rex KGR, Rasmi RR. Targeting the redox neuroinflammatory nexus: insights into Alzheimer’s and Parkinson’s diseases. Inflammopharmacology. 2025;33:3885–95. [DOI] [PubMed]

27.

Scarian E, Viola C, Dragoni F, Di Gerlando R, Rizzo B, Diamanti L, et al. New Insights into Oxidative Stress and Inflammatory Response in Neurodegenerative Diseases. Int J Mol Sci. 2024;25:2698. [DOI] [PubMed] [PMC]

28.

Akanji MA, Rotimi DE, Elebiyo TC, Awakan OJ, Adeyemi OS. Redox Homeostasis and Prospects for Therapeutic Targeting in Neurodegenerative Disorders. Oxid Med Cell Longev. 2021;2021:9971885. [DOI] [PubMed] [PMC]

29.

Akhtar A, Sah SP. Insulin signaling pathway and related molecules: Role in neurodegeneration and Alzheimer’s disease. Neurochem Int. 2020;135:104707. [DOI] [PubMed]

30.

Tong B, Ba Y, Li Z, Yang C, Su K, Qi H, et al. Targeting dysregulated lipid metabolism for the treatment of Alzheimer's disease and Parkinson's disease: Current advancements and future prospects. Neurobiol Dis. 2024;196:106505. [DOI] [PubMed]

31.

Brini M, Calì T, Ottolini D, Carafoli E. Neuronal calcium signaling: function and dysfunction. Cell Mol Life Sci. 2014;71:2787–814. [DOI] [PubMed] [PMC]

32.

Panda SP, Kesharwani A, Datta S, Prasanth DSNBK, Panda SK, Guru A. JAK2/STAT3 as a new potential target to manage neurodegenerative diseases: An interactive review. Eur J Pharmacol. 2024;970:176490. [DOI] [PubMed]

33.

Ashraf A, Bruce ED. A Review of HIF-1α-Mediated Integration of Metabolic Reprogramming, Mitochondrial Function, and PI3K/Akt–MAPK–Nrf2–NF-κB Signaling. Antioxidants. 2026;15:378. [DOI] [PubMed] [PMC]

34.

Li G, Zhang Y, Jiang H, Wu X, Hao Y, Su Y, et al. PPARG/SPP1/CD44 signaling pathway in alveolar macrophages: Mechanisms of lipid dysregulation and therapeutic targets in idiopathic pulmonary fibrosis. Heliyon. 2025;11:e41628. [DOI] [PubMed] [PMC]

35.

Rahimifard M, Maqbool F, Moeini-Nodeh S, Niaz K, Abdollahi M, Braidy N, et al. Targeting the TLR4 signaling pathway by polyphenols: A novel therapeutic strategy for neuroinflammation. Ageing Res Rev. 2017;36:11–9. [DOI] [PubMed]

36.

Sharma V, Sharma P, Singh TG. Mechanistic insights on TLR-4 mediated inflammatory pathway in neurodegenerative diseases. Pharmacol Rep. 2024;76:679–92. [DOI] [PubMed]

37.

Belov AA, Mohammadi M. Grb2, a Double-Edged Sword of Receptor Tyrosine Kinase Signaling. Sci Signal. 2012;5:pe49. [DOI] [PubMed] [PMC]

38.

Matrone C, Petrillo F, Nasso R, Ferretti G. Fyn Tyrosine Kinase as Harmonizing Factor in Neuronal Functions and Dysfunctions. Int J Mol Sci. 2020;21:4444. [DOI] [PubMed] [PMC]

39.

Streicher JM. The Role of Heat Shock Proteins in Regulating Receptor Signal Transduction. Mol Pharmacol. 2019;95:468–74. [DOI] [PubMed]

40.

Roy N, Das R, Paira R, Paira P. Different routes for the construction of biologically active diversely functionalized bicyclo[3.3.1]nonanes: an exploration of new perspectives for anticancer chemotherapeutics. RSC Adv. 2023;13:22389–480. [DOI] [PubMed] [PMC]

41.

Golubeva EA, Lavrov MI, Radchenko EV, Veremeeva PN, Matthews J, Tafeenko VA, et al. Cognitive enhancing and neuroprotective effect of tricyclic cage 3,7-diazabicyclo[3.3.1]nonane derivative. Mendeleev Commun. 2026;36:534–7. [DOI]

42.

Li S, Gao Y, Zhang X, Lang J, Liu X, Zhang Y, et al. Bicyclol improves cognition deficits and inhibits oxidative stress-induced neuronal cell apoptosis in alzheimer’s disease via Nrf2/HO-1 pathway. Metab Brain Dis. 2025;40:310. [DOI] [PubMed]